南微醫學(688029.SH)半年度淨利潤預降25.94%左右
格隆匯 7 月 13日丨南微醫學(688029.SH)公佈,預計2020年半年度實現歸屬於母公司所有者的淨利潤11122.17萬元左右,與上年同期(法定披露數據)相比,將減少3895.86萬元左右,同比減少25.94%左右;
歸屬於母公司所有者的扣除非經常性損益的淨利潤10346.28萬元左右,與上年同期(法定披露數據)相比,將減少4525.13萬元左右,同比減少30.43%左右。
主營業務影響:1、2020年上半年,受新冠疫情影響,國內外醫院內鏡門診和治療人數同比下降。報告期內,公司生產訂單、產品出貨量均有一定幅度下滑,截止本報告期末,境內外醫院內鏡檢查和手術量尚未完全恢復正常,導致營業收入較上年同期出現下降。
2、公司着眼可持續發展,積極謀篇佈局,面對疫情沒有削減在人才引進、產品研發、註冊准入、智能製造和信息化建設的投入,為未來發展蓄力,以至相關費用有一定幅度增長,導致歸屬於上市公司股東的淨利潤較上年同期出現下降。
非經常性損益的影響:1、本期計入損益的政府補助940.80萬元,較上年同期增加801.03萬元,主要原因為本期收到地方政府給予的上市補貼320萬元、美國小企業管理局(U.S. Small Business Administration)根據工資保護計劃(PPP)發放給美國子公司的冠狀病毒援助資金507.56萬元。
2、面對疫情,公司積極投身疫情防控工作,主動承擔社會責任,向公益組織和醫療機構捐贈了用於新冠肺炎疫情的防疫物資及現金共計137.87萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.